Evaluation of a commercial bovine viral diarrhea virus vaccine in nonpregnant female alpacas (Vicugna pacos).
Bovine viral diarrhea virus (BVDV) is an emerging pathogen in alpacas and many questions still persist regarding disease mechanisms and control strategies. The purpose of this study was to evaluate a commercial BVDV vaccine for safety and efficacy in alpacas. Five nonpregnant alpacas were vaccinated with a modified-live BVDV vaccine and challenged 25 days post-immunization by nasal and ocular inoculation with a BVDV Type 1b strain isolated from a confirmed BVDV persistently infected alpaca. Two nonpregnant alpacas served as non-vaccinated controls and were similarly challenged. Results indicated that BVDV virus could not be detected from the vaccinated alpacas but was detected in the unvaccinated alpacas. Results suggest that administration of modified-live BVDV vaccine protected the alpacas in this study from experimental challenge and no adverse effects from the vaccine were observed.
Byers
Stacey R
SR
Department of Veterinary Clinical Sciences, PO Box 647060, Pullman, WA 99164-7060, USA. srbyers@colostate.edu
Evermann
James F
JF
Bradway
Daniel S
DS
Parish
Steven M
SM
Barrington
George M
GM
D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D001769:Blood / Q000821:virology; D002161:Camelids, New World; D030241:Diarrhea Virus 1, Bovine Viral / Q000276:immunology*; D005260:Female; D018182:Pestivirus Infections / Q000517:prevention & control*; D013997:Time Factors; D014765:Viral Vaccines / Q000009:adverse effects* / Q000276:immunology*
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D014765:Viral Vaccines